Based on their high significance in the screen as well as prevalence of loss-of-function somatic mutations in cancers, we performed validation of EXO1 synthetic lethal interactions with FANCM complex factors FAAP24 and APITD1, FA core complex factor FANCG, and BRCA1-A complex factors FAM175A and BRCC3 using clonogenic and viability assays. This evidence concerns the gene EXO1 and cancer.